- About CURE
Samuel French, MD, PhD
Assistant Professor, Department of Pathology and Laboratory Medicine,David Geffen School of Medicine at UCLA
Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death worldwide. One of most common causes of HCC includes infection with hepatitis C virus (HCV) in association with cirrhosis. Dr. French is examining the impact of HCV on hepatocyte cell signaling that leads to hepatocarcinogenesis. He is engaged in a three pronged approach to the relationship between HCV infection and HCC that is yielding significant and potentially medically relevant results. Through a proteomic screens a cellular factor (HSP70) was identified that is important for HCV infection and that compounds that inhibit HSP70 expression can significantly reduce viral infection with minimal associated toxicity. In a bench to bedside fashion he is using this data to test the effect of Quercetin on HCV infection in a clinical trial. Further he has developed several unique compounds that may also have potential as therapeutic agents for the treatment of HCV and the prevention of HCC. He is also characterizing the phosphoproteome of HCV infected cells to identify unique HCV related kinase pathways that could serve as targets for HCV therapy and chemoprevention of HCC. Dr. French has been supported by a Pilot and Feasibility Study award and has been a recent Named New Investigator of the Center. Subsequently, he has been awarded a R01 from NIDDK and consequently, is actively establishing an independent program of digestive diseases-related research.